Penetration of left and right atrial wall and aortic root by an Amplatzer atrial septal occluder in a nine year old boy with Marfan syndrome: Case report
© Loeffelbein et al; licensee BioMed Central Ltd. 2008
Received: 21 May 2007
Accepted: 06 May 2008
Published: 06 May 2008
To describe complications associated with Amplatzer septal occluders in a patient with Marfan syndrome
A nine-year-old boy with Marfan syndrome and a 22 mm atrial septal defect (ASD) was treated successfully by interventional closure of his ASD by placing a 24 mm Amplatzer septal occluder. Follow up examinations showed a good result but an increasing enlargement of aortic root, so the patient was scheduled for operation. Intraoperative findings showed a perforation of the left atrial roof and the non-coronary sinus by penetration of the occluder device as well as penetration into the right atrial wall. The occluder was resected, the ASD was closed and the aortic sinus was reconstructed using a Dacron patch.
We describe the first case of a patient with Marfan syndrome and an interventional closure of an ASD. Due to alterations of the connective tissue, as it is typical for patients with Marfan syndrome, the Amplatzer occluder probably perforated adjacent structures more easily as in non-affected individuals. Amplatzer occluders should be used with caution and follow up examinations should be performed in short intervals.
Marfan syndrome is a relatively common genetic disorder with an estimated prevalence of 1: 3,000 to 1:10,000. It is most often caused by mutations in the FBN1 (Fibrillin) gene [1, 2]. Patients typically present with signs and symptoms related to alterations of their connective tissue including tall stature, recurrent back pain, pectus excavatum, dural ectasia, subluxation of the lens, aneurysm of the aortic root with subsequent aortic regurgitation, and aneurysms of the ascending, descending, or thoracic aorta which can result in rupture and death.
Marfan syndrome is an autosomal dominant disorder with the onset of symptoms occurring in the first decade of life. Nearly 50 percent of patients have to undergo aortic surgery in their lifetime resulting in reconstruction or replacement of the aortic root or total of this vessel's parts . In addition, the occurrence of septal defects in patients with Marfan syndrome is not common.
To our knowledge this is the first description of aortic root perforation by a septal occluder in a patient with Marfan syndrome. There are only a few cases that report destruction of aortic segments after placement of closure devices in patients with patent foramen ovale (PFO), patent ductus arteriosus (PDA) or ASD [4–7]. Perforation is a rare event, occurring in approximately 0.1% of all cases, indicating closure devices are generally safe. The mechanism of perforation is not well understood but it might be related to the absence or presence of the anterosuperior and posteroinferior rims of the atrial septum where the closure device is fixed in position [8, 9]. Interestingly perforations are observed uniquely in the anterosuperior wall and the adjacent aorta .
In patients with an altered connective tissue, the reason for dislocation of closure devices might be different. Thus far, we know that the affected protein Fibrillin in Marfan syndrome, plays a crucial role in maintaining the structure of the connective tissue. With the loss of appropriate structure and therefore rigidity, artificial devices may breach and alter the tissue more easily than in non-affected individuals.
Interventionally applied stents that are used to treat thoracic aortic aneurysms in patients with Marfan syndrome  are possibly less harmful. Shear forces on the aortic wall are reduced significantly and the vessels are protected from these. Closure devices in septal walls move constantly and may be subjected to greater shearing forces. This can result, as shown in our patient, in deterioration of clinical findings, i.e. augmentation of aortic root's diameter, penetration of adjacent structures, dislocation of the device and the need for early heart or aortic surgery.
Patients with Marfan disease may be at elevated risk for penetration of Amplatzer devices. As long as it is not possible to estimate the individual risk by molecular methods, and the mechanism of penetration is poorly understood, in our opinion, the use of septal occluders should be considered with caution. Even though there are a number of alternative occluders such as the Helex and the Sideris Patch, that may be less rigid, reports of their use in patients with Marfan syndrome are nonexistent. Complication rate, deterioration, and the need of reoperation may occur at an extended level. Thus follow up examinations in those patients should be applied in short intervals. Taking in account these considerations, we would prefer surgery.
Written consent was obtained from the patient or their relative for publication of study.
- Magenis RE, Maslen CL, Smith L, Allen L, Sakai LY: Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics. 1991, 11: 346-351.View ArticlePubMedGoogle Scholar
- McKusick VA: The defect in Marfan syndrome. Nature. 1991, 352: 279-281. 10.1038/352279a0.View ArticlePubMedGoogle Scholar
- Groenink M, Lohuis TA, Tijssen JG, Naeff MS, Hennekam RC, Wall van der EE, Mulder BJ: Survival and complication free survival in Marfan's syndrome: implications of current guidelines. Heart. 1999, 82: 499-504.View ArticlePubMedPubMed CentralGoogle Scholar
- Cecconi M, Quarti A, Bianchini F, Bucari S, Costantini C, Giovagnoni A, Perna GP: Late cardiac perforation after transcatheter closure of patent foramen ovale. Ann Thorac Surg. 2006, 81: e29-30. 10.1016/j.athoracsur.2006.02.057.View ArticlePubMedGoogle Scholar
- Ewert P, Kretschmar O, Peters B, Nuernberg JH, Khaliq HA, Nagdyman N, Lange PE: Preliminary experience with a new 18 mm Amplatzer PFO occluder for small persistent foramen ovale. Catheter Cardiovasc Interv. 2003, 59: 518-521. 10.1002/ccd.10577.View ArticlePubMedGoogle Scholar
- Grayburn PA, Schwartz B, Anwar A, Hebeler RF: Migration of an amplatzer septal occluder device for closure of atrial septal defect into the ascending aorta with formation of an aorta-to-right atrial fistula. Am J Cardiol. 2005, 96: 1607-1609. 10.1016/j.amjcard.2005.08.013.View ArticlePubMedGoogle Scholar
- Sauer HH, Ntalakoura K, Haun C, Le TP, Hraska V: Early cardiac perforation after atrial septal defect closure with the Amplatzer septal occluder. Ann Thorac Surg. 2006, 81: 2312-2313. 10.1016/j.athoracsur.2005.08.008.View ArticlePubMedGoogle Scholar
- Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS: Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004, 63: 496-502. 10.1002/ccd.20211.View ArticlePubMedGoogle Scholar
- Trepels T, Zeplin H, Sievert H, Billinger K, Krumsdorf U, Zadan E, Horvath K: Cardiac perforation following transcatheter PFO closure. Catheter Cardiovasc Interv. 2003, 58: 111-113. 10.1002/ccd.10371.View ArticlePubMedGoogle Scholar
- Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J: Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. 2005, 45: 1213-1218. 10.1016/j.jacc.2004.12.072.View ArticlePubMedGoogle Scholar
- Ince H, Rehders TC, Petzsch M, Kische S, Nienaber CA: Stent-grafts in patients with marfan syndrome. J Endovasc Ther. 2005, 12: 82-88. 10.1583/04-1415MR.1.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.